FULC insider transaction filings
Fulcrum Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-20. Screen FULC transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 11 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 6 legs across 2 filings by 2 insiders — 417,562 shares, $1,485,743 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 1 leg across 1 filing by 1 insider — 18,000 shares, $65,614 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 8.
- Largest priced transaction: purchase of 116,671 shares @ $3.56 ($415,349) by TANG KEVIN, filed 2026-07-20.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| TANG KEVIN — 10% owner & TANG CAPITAL MANAGEMENT LLC — 10% owner | 2 | 6 legs · 417,562 sh · $1,485,743 | — | — |
| Ezekowitz Alan — Director | 2 | — | 1 leg · 18,000 sh · $65,614 | 1 |
| Banks Sonja — Director | 1 | — | — | 1 |
| Dorton Katina — Director | 1 | — | — | 1 |
| GERAGHTY JAMES A — Director | 1 | — | — | 1 |
| Gould Robert J — Director | 1 | — | — | 1 |
| Haviland Kate — Director | 1 | — | — | 1 |
| Hill Colin — Director | 1 | — | — | 1 |
| King Rachel K. — Director | 1 | — | — | 1 |
Recent Form 4 filings — Fulcrum Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-20 | 4 | TANG KEVIN — 10% owner TANG CAPITAL MANAGEMENT LLC — 10% owner | Purchase (P): 116,671 @ $3.56 · Purchase (P): 50,945 @ $3.52 | EDGAR |
| 2026-07-15 | 4 | TANG KEVIN — 10% owner TANG CAPITAL MANAGEMENT LLC — 10% owner | Purchase (P): 12,966 @ $3.54 · Purchase (P): 53,651 @ $3.56 · Purchase (P): 75,952 @ $3.58 · Purchase (P): 107,377 @ $3.56 | EDGAR |
| 2026-07-02 | 4 | Banks Sonja — Director | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Ezekowitz Alan — Director | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Hill Colin — Director | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Haviland Kate — Director | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Dorton Katina — Director | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | King Rachel K. — Director | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Gould Robert J — Director | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | GERAGHTY JAMES A — Director | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Ezekowitz Alan — Director | Sale (S): 18,000 @ $3.65 | EDGAR |
| 2026-05-01 | 4 | Lehrer-Graiwer Joshua — Director | Grant/award (A): 64,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Oltmans Curtis Gale — Chief Legal Officer | Grant/award (A): 170,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Tourangeau Greg — Principal Accounting Officer | Grant/award (A): 57,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Sapir Alex — See Remarks, Director | Grant/award (A): 650,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Gould Robert J — Director | Sale (S): 15,000 @ $10.72 | EDGAR |
| 2026-02-04 | 4/A | Gould Robert J — Director | Sale (S): 15,000 @ $10.87 | EDGAR |
| 2026-02-04 | 4 | Musso Alan A — Chief Financial Officer | Grant/award (A): 170,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Gould Robert J — Director | Sale (S): 15,000 @ $11.87 | EDGAR |
| 2025-12-17 | 4 | Oltmans Curtis Gale — Chief Legal Officer | Sale (S): 3,452 @ $12.92 | EDGAR |
| 2025-12-10 | 4 | RA CAPITAL MANAGEMENT, L.P. — 10% owner RA Capital Healthcare Fund LP — 10% owner Kolchinsky Peter — 10% owner Shah Rajeev M. — 10% owner | Sale (S): 1,377,020 @ $13.33 · Sale (S): 2,706,397 @ $14.28 · Sale (S): 91,722 @ $14.98 | EDGAR |
| 2025-11-21 | 4 | Gould Robert J — Director | Sale (S): 15,000 @ $11.03 | EDGAR |
| 2025-06-30 | 4 | Banks Sonja — Director | Grant/award (A): 36,000 (derivative) @ $0 | EDGAR |
| 2025-06-30 | 4 | Ezekowitz Alan — Director | Grant/award (A): 36,000 (derivative) @ $0 | EDGAR |
| 2025-06-30 | 4 | Hill Colin — Director | Grant/award (A): 36,000 (derivative) @ $0 | EDGAR |
| 2025-06-30 | 4 | Haviland Kate — Director | Grant/award (A): 36,000 (derivative) @ $0 | EDGAR |
| 2025-06-30 | 4 | Dorton Katina — Director | Grant/award (A): 36,000 (derivative) @ $0 | EDGAR |
| 2025-06-30 | 4 | King Rachel K. — Director | Grant/award (A): 36,000 (derivative) @ $0 | EDGAR |
| 2025-06-30 | 4 | Gould Robert J — Director | Grant/award (A): 36,000 (derivative) @ $0 | EDGAR |
| 2025-06-30 | 4 | GERAGHTY JAMES A — Director | Grant/award (A): 36,000 (derivative) @ $0 | EDGAR |
| 2025-05-09 | 4 | Tourangeau Greg — Principal Accounting Officer | Sale (S): 498 @ $5.06 | EDGAR |
| 2025-01-28 | 4 | Sapir Alex — See Remarks, Director | Grant/award (A): 582,000 (derivative) @ $0 | EDGAR |
| 2025-01-28 | 4 | Tourangeau Greg — Principal Accounting Officer | Grant/award (A): 76,120 (derivative) @ $0 | EDGAR |
| 2025-01-28 | 4 | Oltmans Curtis Gale — Chief Legal Officer | Grant/award (A): 225,000 (derivative) @ $0 | EDGAR |
| 2025-01-28 | 4 | Musso Alan A — Chief Financial Officer | Grant/award (A): 285,000 (derivative) @ $0 | EDGAR |
| 2024-11-14 | 4 | King Rachel K. — Director | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2024-08-23 | 4 | RA CAPITAL MANAGEMENT, L.P. — 10% owner RA Capital Healthcare Fund LP — 10% owner Kolchinsky Peter — 10% owner Shah Rajeev M. — 10% owner | Other (J): 8,500,000 · Other (J): 8,500,000 (derivative) | EDGAR |
| 2024-07-08 | 4 | Sapir Alex — See Remarks, Director | Option exercise (M): 150,000 @ $3.27 · Option exercise (M): 150,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Ezekowitz Alan — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Collins James J. — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Banks Sonja — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Hill Colin — Director | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Haviland Kate — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Dorton Katina — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Gould Robert J — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | GERAGHTY JAMES A — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-05-09 | 4 | Tourangeau Greg — Principal Accounting Officer | Sale (S): 236 @ $7.76 | EDGAR |
| 2024-03-20 | 4 | Horn Patrick Taylor — Chief Medical Officer | Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2024-03-08 | 4 | Tourangeau Greg — Vice President, Finance | Sale (S): 4,884 @ $11.72 | EDGAR |
| 2024-03-05 | 4 | Sapir Alex — See Remarks, Director | Purchase (P): 43,360 @ $11.35 | EDGAR |
Recent 8-K events — Fulcrum Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-10 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-25 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-06-11 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-04 | 8-K | ? 8.01 — Other Events | EDGAR |
| 2026-06-01 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-27 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-24 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-11 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=FULC returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →